Wolfhard Frost · Bessemerweg 13 · 33611 Bielefeld
E-Mail: info@prostata-sh.info

PSA Selbsthilfegruppe Prostatakrebs Bielefeld



im November 2007 zeigte eine Phase III Studie:

CONCLUSIONS. Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden.

Der PK-spezifische Überlebensvorteil war so gut wie nicht vorhanden.

In den Foren in den USA war zu lesen: About a decade ago, Abbott Laboratories started to investigate the potential of a selective endothelin receptor antagonist called atrasentan or Xinlay™ for the treatment of advanced forms of prostate cancer.

A randomized Phase II trial initially suggested that atrasentan might be an effective form of treatment for hormone-refractory disease, but two later, randomized, double-blind, placebo-controlled, Phase III clinical trials showed no efficacy of atrasentan monotherapy in the management of either metastatic, castration-resistant prostate cancer (mCRPC) or non-metastatic, castration-resistant disease.

Dezember 2011